Sosei and Novartis announced that the first three Phase 3 studies of QVA149 (indacaterol 110mcg/glycopyrronium bromide 50mcg) in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.